Skip to content
Screener
Q2 '26Q1 '26Q4 '25Q3 '25Q2 '25
-$47.32M+57.6%-$79.05M+32.0%-$71.9M+8.5%-$91.25M-9.2%-$111.66M-15.0%
$3.78M+11.3%$2.82M+9.8%$3.72M+13.7%$3.19M+6.3%$3.4M+13.3%
$11.73M-21.5%$11.27M-50.8%$11.82M-61.9%$11.9M-61.6%$14.94M-51.0%
-$60.84M+9.8%-$72.07M+30.5%-$52.57M+28.3%-$78.7M-33.5%-$67.45M+31.5%
$5.44M-27.1%$6.61M+6.4%$9.32M+124%$10.84M+374%$7.46M+1,588%
-$74.05M-635%$11.39M-28.2%$775K$17.01M+135%$13.84M
$49.29M+273%$94.34M-34.2%$56.17M+2,333%$88.06M+110%$13.23M-91.3%
-$85.73M$33.44M-40.3%$4.96M+110%$25.69M+140%
-$66.28M+11.5%-$78.68M+28.4%-$61.89M+20.1%-$89.55M-46.2%-$74.91M+24.2%

FAQ

How much cash does Iovance Biotherapeutics, Inc. generate?
Iovance Biotherapeutics, Inc. (IOVA) generated -$264.2M in operating cash flow over the trailing twelve months.
What is Iovance Biotherapeutics, Inc.'s free cash flow?
After $32.2M of capital expenditures, Iovance Biotherapeutics, Inc.'s free cash flow was -$296.4M over the trailing twelve months, up 8.4% year over year.
Where does Iovance Biotherapeutics, Inc.'s cash flow data come from?
Every line is extracted from Iovance Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.